Sangamo Therapeutics has patented compositions for creating non-naturally occurring nucleases by linking DNA binding domains and cleavage domains. The patent also covers methods for making and using these compositions. The invention involves dimers with fusion molecules binding to specific target sites and cleaving DNA. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Non-naturally occurring nucleases with alternative configurations
A recently granted patent (Publication Number: US11920169B2) discloses a novel dimer structure comprising first and second fusion molecules. The first fusion molecule includes a DNA binding domain that binds to a specific target site and a cleavage domain, while the second fusion molecule also contains a DNA-binding domain and a cleavage domain. When the DNA-binding domains are bound to target sites separated by 7 base pairs, the cleavage domains dimerize, allowing for precise modification of cellular chromatin. The dimer can introduce insertions, deletions, or integrate donor sequences into the cellular chromatin, offering a versatile tool for genetic manipulation.
Furthermore, the patent covers variations of the dimer structure with different base pair separations between target sites, such as 8 and 9 base pairs. These dimers function similarly to the original design, enabling targeted modifications of cellular chromatin. The patent also includes methods for introducing the dimers into cells using polynucleotides and provides kits for facilitating the modification process. Overall, this patented technology offers a promising approach for precise genetic engineering and manipulation of cellular chromatin, with potential applications in various fields such as biotechnology, medicine, and research.
To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
